Research ArticleClinical Investigation
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)
Fabien Ricard, Bruce Cheson, Sally Barrington, Judith Trotman, Annette Schmid, Guenther Brueggenwerth, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann and Ron Korn
Journal of Nuclear Medicine January 2023, 64 (1) 102-108; DOI: https://doi.org/10.2967/jnumed.122.264106
Fabien Ricard
1Relay Therapeutics, Cambridge, Massachusetts;
Bruce Cheson
2Lymphoma Research Foundation, New York, New York;
Sally Barrington
3King’s College London and Guy’s and St. Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, King’s College London, King’s Health Partners, London, United Kingdom;
Judith Trotman
4Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia;
Annette Schmid
5Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts;
Guenther Brueggenwerth
6Bayer AG, Berlin, Germany;
Gilles Salles
7Department of Medicine, Memorial Sloan Kettering Cancer Center and Weil Cornell Medicine, New York, New York;
Larry Schwartz
8Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, Columbia, New York;
Greg Goldmacher
9Merck and Co, Inc., Kenilworth, New Jersey;
Rudresh Jarecha
10Deciphera Pharmaceuticals LLC, Waltham, Massachusetts;
Jayant Narang
5Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts;
Florence Broussais
11LYSARC, Pierre Benite, France;
Paul Galette
12GSK, Collegeville, Pennsylvania;
Min Liu
13Autolus Therapeutics, London, United Kingdom;
Surabhi Bajpai
14Calyx International, Billerica, Massachusetts;
Eric Perlman
15Perlman Advisory Group LLC, Boynton Beach, Florida;
Julie Gillis
16Merigold LLC, Branford, Connecticut;
Ira Smalberg
17Saint John’s Cancer Institute and Tower Imaging Medical Group, Sherman Oaks, California;
Pierre Terve
18KEOSYS Medical Imaging, Saint Herblain, France;
Gudrun Zahlmann
19Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, Illinois; and
Ron Korn
20TGEN/City of Hope and Imaging Endpoints Core Lab, Scottsdale, Arizona
Article Figures & Data
Figures
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 64, Issue 1
January 1, 2023
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)
Fabien Ricard, Bruce Cheson, Sally Barrington, Judith Trotman, Annette Schmid, Guenther Brueggenwerth, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Ron Korn
Journal of Nuclear Medicine Jan 2023, 64 (1) 102-108; DOI: 10.2967/jnumed.122.264106
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)
Fabien Ricard, Bruce Cheson, Sally Barrington, Judith Trotman, Annette Schmid, Guenther Brueggenwerth, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Ron Korn
Journal of Nuclear Medicine Jan 2023, 64 (1) 102-108; DOI: 10.2967/jnumed.122.264106
Jump to section
- Article
- Visual Abstract
- Abstract
- MATERIALS AND METHODS
- IMAGING ACQUISITION CONSIDERATIONS
- FDG AVIDITY OF LYMPHOMA ENTITIES
- LESION CLASSIFICATION, SCORING, AND RESPONSE NOMENCLATURE
- RESPONSE ASSESSMENT
- INCORPORATION OF CLINICAL DATA
- EVALUATION OF SPLEEN, LIVER, AND NODAL INVOLVEMENT
- CONCLUSION
- DISCLOSURE
- ACKNOWLEDGMENTS
- Footnotes
- REFERENCES
- Figures & Data
- Supplemental
- Info & Metrics
Related Articles
Cited By...
- Development of 18F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance
- Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2--Technical)